Therapeutic monitoring of TNF-alpha inhibitors in Crohn’s disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits)

Evidence-based recommendations on therapeutic monitoring of tumour necrosis factor (TNF)‑alpha inhibitors (LISA‑TRACKER, IDKmonitor and Promonitor ELISA kits) in people with Crohn’s disease.

During development of this guidance, NICE became aware that the RIDASCREEN IFX Monitoring (R-Biopharm) ELISA kit for monitoring infliximab levels received a CE mark. This new test is based on the Leuven in-house ELISA. For further information please see NICE’s medtech innovation briefing on RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease.

Last reviewed: 17 February 2016

Diagnostics guidance 22 has been migrated to HealthTech guidance 401.

Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.

Guidance development process

How we develop diagnostics guidance